On Tuesday, Shares of Aduro BioTech Inc (NASDAQ:ADRO), lost -16.07% to $27.05.
Aduro Biotech, declared that the European Medicines Agency (EMA) granted Orphan Drug Designation to CRS-207 for the treatment of malignant pleural mesothelioma (MPM).
“The receipt of Orphan Drug Designation in the European Union (EU) for CRS-207 for the treatment of MPM marks a noteworthy regulatory milestone for Aduro, as we expand our operations in Europe and advance our therapies closer to the commercial marketplace,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “We look forward to working with the EMA to expeditiously advance CRS-207 through development with the aim of bringing this potential therapy to patients throughout Europe suffering from mesothelioma.”
To receive Orphan Drug Designation from the EMA, a therapy must be intended for the treatment of a life-threatening or chronically debilitating rare condition with a prevalence of less than five in 10,000 in the European Union. Orphan Drug Designation provides incentives designed to facilitate development, counting protocol assistance and scientific advice and importantly, may provide up to ten years of market exclusivity in the EU following product approval.
Aduro Bio Tech, Inc., a clinical-stage immuno-oncology company, focuses on the development of technology platforms designed to stimulate robust and durable immune responses against cancer.
Shares of Texas Instruments Incorporated (NASDAQ:TXN), inclined 0.87% to $57.85, during its last trading session.
Texas Instruments Incorporated, Executive Vice President of Business Operations Brian Crutcher will speak at the 2015 Credit Suisse 19th Annual Technology Conference in Scottsdale, Ariz. on Tuesday, December 1, at 10:30 a.m. Mountain time. Crutcher will field questions from analysts and investors, in addition to discuss TI’s business outlook and its strategy to address key markets for its analog and embedded processing technologies and how these capabilities position the company for growth.
Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers worldwide. It operates through two segments, Analog and Embedded Processing.
Finally, Shares of Lululemon Athletica inc. (NASDAQ:LULU), ended its last trade with -0.08% loss, and closed at $52.73.
lululemon athletica inc., declared that its financial results for the third quarter fiscal year 2015 will be released Wednesday, December 9, 2015. The company will host a conference call at 9:00 a.m. Eastern time to discuss the financial results.
lululemon athletica inc., together with its auxiliaries, designs, manufactures, and distributes athletic apparel and accessories for women, men, and female youth. It operates through two segments, Corporate-Owned Stores and Direct To Consumer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
